Kim J, Kim H, Kim W, Lee E, Kim S, Kim T
Signal Transduct Target Ther. 2025; 10(1):15.
PMID: 39828766
PMC: 11743776.
DOI: 10.1038/s41392-024-02106-6.
Zhao X, Xuan F, Li Z, Yin X, Zeng X, Chen J
NPJ Vaccines. 2025; 10(1):1.
PMID: 39753573
PMC: 11699128.
DOI: 10.1038/s41541-024-01060-2.
Zhan Y, Mao Y, Sun P, Liu C, Gou H, Qi H
Mikrochim Acta. 2024; 191(5):248.
PMID: 38587676
DOI: 10.1007/s00604-024-06331-2.
Liu H, Sun L, Yu L, Liu J, Sun L, Yang Z
Stem Cell Res Ther. 2023; 14(1):273.
PMID: 37759328
PMC: 10523703.
DOI: 10.1186/s13287-023-03453-x.
Zhu P, Li S, Ding J, Fei Z, Sun S, Zheng Z
J Pharm Anal. 2023; 13(6):616-624.
PMID: 37440907
PMC: 10334272.
DOI: 10.1016/j.jpha.2023.04.012.
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.
Anand U, Dey A, Chandel A, Sanyal R, Mishra A, Pandey D
Genes Dis. 2023; 10(4):1367-1401.
PMID: 37397557
PMC: 10310991.
DOI: 10.1016/j.gendis.2022.02.007.
Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma.
Hu X, Liu T, Li L, Gan H, Wang T, Pang P
Turk J Gastroenterol. 2023; 34(6):635-644.
PMID: 37162505
PMC: 10441129.
DOI: 10.5152/tjg.2023.22134.
Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings.
Wei Y, Yang M, Xu L, Liu M, Zhang F, Xie T
Cancers (Basel). 2023; 15(3).
PMID: 36765615
PMC: 9913645.
DOI: 10.3390/cancers15030658.
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
Zhang Y, Yang Y, Chen Y, Lin W, Chen X, Liu J
Front Immunol. 2022; 13:1060497.
PMID: 36505487
PMC: 9729722.
DOI: 10.3389/fimmu.2022.1060497.
Clinically approved combination immunotherapy: Current status, limitations, and future perspective.
Lu L, Zhan M, Li X, Zhang H, Dauphars D, Jiang J
Curr Res Immunol. 2022; 3:118-127.
PMID: 35676925
PMC: 9167882.
DOI: 10.1016/j.crimmu.2022.05.003.
Application of Organoids in Carcinogenesis Modeling and Tumor Vaccination.
Wang Z, Zhao S, Lin X, Chen G, Kang J, Ma Z
Front Oncol. 2022; 12:855996.
PMID: 35371988
PMC: 8968694.
DOI: 10.3389/fonc.2022.855996.
The B-Cell-Specific Ablation of B4GALT1 Reduces Cancer Formation and Reverses the Changes in Serum IgG Glycans during the Induction of Mouse Hepatocellular Carcinoma.
Sha J, Zhang R, Fan J, Gu Y, Pan Y, Han J
Cancers (Basel). 2022; 14(5).
PMID: 35267641
PMC: 8909634.
DOI: 10.3390/cancers14051333.
Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma.
Zaki M, Fathi A, Samir S, Eldafashi N, Y William K, Nazmy M
Cancers (Basel). 2022; 14(5).
PMID: 35267563
PMC: 8909759.
DOI: 10.3390/cancers14051255.
NAFLD indirectly impairs antigen-specific CD8 T cell immunity against liver cancer in mice.
McVey J, Green B, Ruf B, McCallen J, Wabitsch S, Subramanyam V
iScience. 2022; 25(2):103847.
PMID: 35198900
PMC: 8844694.
DOI: 10.1016/j.isci.2022.103847.
TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes.
Sun H, Kim E, Ryu J, Lee H, Shin E, Lee M
Cell Mol Life Sci. 2021; 79(1):49.
PMID: 34921636
PMC: 8739317.
DOI: 10.1007/s00018-021-04051-x.
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M
Front Immunol. 2021; 12:765101.
PMID: 34675942
PMC: 8524467.
DOI: 10.3389/fimmu.2021.765101.
LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma.
Liu F, Hou W, Liang J, Zhu L, Luo C
J Cancer. 2021; 12(13):4039-4048.
PMID: 34093808
PMC: 8176260.
DOI: 10.7150/jca.53124.
Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma.
Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L
Front Immunol. 2021; 12:650486.
PMID: 34025657
PMC: 8137829.
DOI: 10.3389/fimmu.2021.650486.
CD8 T Cell Responses during HCV Infection and HCC.
Hofmann M, Tauber C, Hensel N, Thimme R
J Clin Med. 2021; 10(5).
PMID: 33801203
PMC: 7957882.
DOI: 10.3390/jcm10050991.
Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis.
You H, Yuan D, Bi Y, Zhang N, Li Q, Tu T
Cell Commun Signal. 2021; 19(1):33.
PMID: 33722250
PMC: 7958410.
DOI: 10.1186/s12964-021-00714-1.
